Related Experiment Videos
Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice
1University of Washington School of Pharmacy, Seattle, USA.
The American Journal of Managed Care
|December 21, 2004
Summary
Warfarin therapy for atrial fibrillation (AF) significantly reduces stroke risk but is underused. Many eligible patients do not receive adequate anticoagulation, leading to preventable strokes and deep vein thrombosis (DVT).
Area of Science:
- Cardiology
- Pharmacology
- Clinical Practice
Background:
- Atrial fibrillation (AF) significantly elevates stroke risk.
- Warfarin therapy is recommended for AF patients to prevent stroke.
- Warfarin's narrow therapeutic index necessitates regular monitoring, posing challenges.
Purpose of the Study:
- To explore the extent of warfarin underutilization and underanticoagulation in clinical practice.
- To describe the clinical consequences of suboptimal warfarin use.
- To discuss the gap between clinical trial outcomes and real-world practice for anticoagulation.
Main Methods:
- Review of current clinical practice regarding warfarin use in AF and DVT prophylaxis.
- Analysis of studies reporting warfarin utilization rates and therapeutic range maintenance.
- Discussion of clinical consequences and economic implications of anticoagulation gaps.
Main Results:
- Less than half of warfarin-eligible AF patients receive the drug in many health systems.
- Adequate anticoagulation within the therapeutic range is achieved by even fewer patients.
- Deep vein thrombosis (DVT) prophylaxis, even post-orthopedic surgery, is often suboptimal.
Conclusions:
- Significant underutilization and underanticoagulation of warfarin exist in current practice.
- This treatment gap leads to increased risks of stroke and DVT.
- Addressing the causes and economic implications is crucial for improving patient outcomes.